The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell Lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response
Introduction: Mantle cell lymphoma (MCL) can be stratified into blastoid and classical subtypes based on morphological features, with the former subtype having a poorer prognosis. Despite recent advances in targeted approaches, including multiple bruton tyrosine kinase inhibitors which yield impress...
Main Authors: | Sheng Yuan MS, Wei Zuo MS, Tingting Liu MS, Huan Fu MS |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-10-01
|
Series: | Technology in Cancer Research & Treatment |
Online Access: | https://doi.org/10.1177/15330338231208608 |
Similar Items
-
Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes
by: Jiang J, et al.
Published: (2023-11-01) -
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
by: Nina Nguyen, et al.
Published: (2022-10-01) -
Profiling DNA damage response following mitotic perturbations
by: Ronni S. Pedersen, et al.
Published: (2016-12-01) -
P1259: CHARACTERIZATION OF VENETOCLAX RESISTANCE IN CELL MODELS OF MANTLE CELL LYMPHOMA
by: A. Granau, et al.
Published: (2022-06-01) -
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
by: Nicola Sgherza, et al.
Published: (2021-09-01)